MONTREAL, April 26, 2013 /PRNewswire-iReach/ -- Micropharma Limited, a pioneer in the development of innovative and effective products based on the human microbiome, today announced that after three years of development it has a timeline for launch of its ingestible gastrointestinal sampling technology. The company released its plans to launch the device in late 2014 commercially for research and development use and later for specific clinical applications. Micropharma has been developing the device for three years and in the last year has expedited the project by partnering with StarFish Medical a medical device development company that offers a full complement of design and manufacturing solutions. The partnership will see StarFish Medical improve and finalize the design of the autonomous multiple sample acquisition and localization technologies, design for manufacture, produce initial devices, as well as to engineer for cost effectiveness.
Micropharma's chief scientific officer Dr. Mitchell Jones commented on the advantages of sampling the GI mucosa over the evaluation of fecal samples by saying "our ingestible pill can sample the mucosa at pre-determined locations throughout the GI tract, including the small intestine. The device is programmable, acts autonomously and can take multiple, large, discrete samples that can be evaluated for human genomic, metabolomic and human gut microbiome data; of immediate and specific interest is to improve samples for microbiome research" he commented further that "protecting the intellectual property was an important part of the commercial development process and we are pleased to have recently filed an international PCT patent application" and that "sampling the gastrointestinal tract allows for site-specific an
|SOURCE Micropharma Limited|
Copyright©2012 PR Newswire.
All rights reserved